Abstract
Introduction
COVID-19 infection is expected to be associated with an increased likelihood of erectile dysfunction (ED). Considering the high transmissibility of COVID-19, ED may be a concerning consequence for a large segment of the population.
Aims
To (1) summarize existing published evidence for the impact of COVID-19 on the prevalence, severity, treatment, and management of ED; and (2) identify health-related trends in the emerging literature and identify gaps in the existing research literature and make recommendations for future research needs in the area.
Methods
A scoping literature search was conducted on April 27, 2021. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (Preferred Reporting Items for Systematic Reviews and Meta-Analyses-ScR) checklist was followed. The literature search was performed in PubMed using the terms: COVID-19, erectile, sexual, and dysfunction. A total of 693 publications were screened for relevance. Studies were appraised for their level of evidence based on study design and the rigor of methodology.
Results
The evidence that COVID-19 infection causes or impacts ED is compelling. Four topics emerged regarding the nature of the association between COVID-19 and ED: (1) the biological impact of COVID-19 infection on ED; (2) the mental health impact of COVID-19 on ED; (3) the impact of COVID-19 on the management of ED and access to ED treatment; and (4) health disparities and the impact of COVID-19 on ED. Long-term and well-designed studies are needed to clarify the extent of the impact of COVID-19 on ED. The pandemic exposed several vulnerabilities within worldwide healthcare and social systems.
Conclusion
COVID-19 has a uniquely harmful impact on men's health and erectile function through biological, mental health, and healthcare access mechanisms. As the pandemic wanes, strategies to identify long-term effects and additional health care support may be needed to adequately mitigate the impact of COVID-19 on men's health.
Hsieh T-C, Edwards NC, Bhattacharyya SK, et al.The Epidemic of COVID-19-Related Erectile Dysfunction: A Scoping Review and Health Care Perspective. Sex Med Rev 2022;10:286–310.
Abbreviations: ACE2, angiotensin-converting enzyme 2; BMI, body mass index; ED, erectile dysfunction; FSFI, female sexual function index; IIEF, international index of erectile function; IL, interleukin; IQR, interquartile range; IS, intercourse satisfaction; NHANES, national health and nutrition examination survey; OS, overall satisfaction; PRISMA, preferred reporting items for systematic reviews and meta-analyses; PRISMA-ScR, preferred reporting items for systematic reviews and meta-analyses extension for scoping reviews; PTSD, post-traumatic stress disorder; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, sexual desire; TNF, tumor necrosis factor
Key Words: Erectile Dysfunction, COVID-19, Scoping Review, Biological, Mental Health, Men's Health
INTRODUCTION
The COVID-19 pandemic has had a devastating impact on the health and wellbeing of people across the world. The uniquely harmful impact of the virus on men's health is becoming more apparent and is more commonly being documented in the published medical literature.1, 2, 3 Men have been shown to have an increased risk of both developing the severe form of COVID-19 and dying from it.3 , 4 Biological (sex) and socio-cultural (gender) factors, compounded by socio-economic factors and ethnicity, have had a marked impact on the aftermath of COVID-19.2 , 3 Testosterone has been identified as a bivalent risk factor for poor prognosis (high/normal in younger; lower in elderly) in COVID-19.1 It has been postulated that testosterone may facilitate SARS-CoV-2 entry in human cells and men may develop a blunted immune response against SARS-CoV-2, being exposed to less viral clearance and more viral shedding and systemic spread of the disease.1 Low levels of serum testosterone observed in men, on the other hand, may predispose them to greater background systemic inflammation, cardiovascular and metabolic diseases, and immune system dysfunction from COVID-19 infection, hence potentially enhancing the long-term consequences of the virus.1 Even men who have never contracted COVID-19 have had their lives severely affected by the pandemic both physically and emotionally as it has caused widespread disruption to normal existence, men's social world, preventative health and healthcare access, and the economy.2
One of the repercussions of COVID-19 is its impact on men's sexual health. COVID-19 infection is expected to be associated with an increased likelihood of erectile dysfunction (ED). Considering the high transmissibility of COVID-19, ED could be a concerning consequence for a large segment of the population.5 However, to our knowledge, the evidence for the association between COVID-19 and ED has not been collectively gathered, integrated, and appraised. The objectives of this study were to conduct a scoping literature review to: (1) summarize existing published evidence for the impact of COVID-19 on the prevalence, severity, treatment, and management of ED; and (2) identify health-related trends in the emerging literature and identify gaps in the existing research literature and make recommendations for future research needs in the area.
MATERIALS AND METHODS
The approach for the literature review was a scoping review given the heterogenous nature of the body of literature describing the relationship between COVID-19 and ED.6 Scoping reviews are a relatively new approach to evidence synthesis.7 They can synthesize research evidence and categorize or group existing literature in a given field in terms of its nature, features, and volume.8 Researchers may conduct scoping reviews instead of traditional reviews when the purpose of the review is to identify knowledge gaps, scope a body of literature, clarify concepts, or to investigate research conduct.7 Scoping reviews may also be helpful precursors to traditional systematic reviews and can be used to confirm the relevance of inclusion criteria and potential questions.7 They deliberately cast a wider net to identify topics that are connected but not necessarily completely within the topic of interest in order to help better discern boundaries of relevant literature. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Extension for Scoping Reviews (PRISMA-ScR) Checklist9 was followed and adhered to in conducting the scoping literature review.
The literature review used the PubMed search engine and was conducted on April 27, 2021 with the search terms “COVID-19″, “erectile”, “sexual”, and “dysfunction”. A total of 693 publications were obtained using the search strategy Studies were included if they provided information about the relationship between COVID-19 and ED or if they discussed patients’ experience of care during COVID-19. All studies underwent a title and abstract screening, and potentially relevant citations were checked in a full-text screening. Reference lists of selected articles were also reviewed for additional possible sources of information (Figure 1 ). Data extracted included the journal citation, publication year, country of origin, study design, and a summary of the pertinent findings. Studies were appraised for their level of evidence based on study design and the rigor of methodology used, as well as the ability to prevent and/or control for biases to analyze cause and effect.
Figure 1.
PRISMA flow diagram of article selection.
RESULTS
A total of 60 studies were selected for inclusion in the scoping review. Table 1 presents the characteristics of the included studies and a summary of their findings. Twenty-three studies (38.3%) were from the US, 10 were from Italy (16.7%), 6 were from China (10.0%), 5 were from Turkey (8.3%), 4 were from India (6.7%), 2 each were from Canada, Greece, and Brazil (3.3%), and 1 each were from Japan, Iran, the UK, the Netherlands, Egypt, Finland, and Portugal (1.7%) (note that one study was from the US and Iran). Twenty-five studies were narrative/literature reviews (41.7%), 12 were patient surveys (20.0%), 11 (18.3%) were expert commentaries/editorials, three were retrospective database evaluations (5.0%), two were urologist surveys (3.3.%), two were systematic reviews/meta-analyses (3.3%), and one each was a prospective cohort study, a retrospective chart review, a case series, a case report, and laboratory/pre-clinical research (1.7%).
Table 1.
Characteristics of the included studies and a summary of the findings
Topic |
|||||||
---|---|---|---|---|---|---|---|
Study | Country of Origin | Study Design | Findings | Biological Impact | Mental Health Impact | Access to Care Impact | Health Disparities |
Lisco et al 20211 | Italy | Narrative Review |
|
√ | |||
Pijls et al 20204 | Netherlands | Systematic Review & Meta-Analysis |
|
√ | |||
Duran et al 202110 | Turkey | Multi-center retrospective chart review |
|
√ | |||
Sansone et al 202111 | Italy | Patient Survey |
|
√ | |||
Jin et al 202012 | China | Narrative Review |
|
√ | |||
Konstantinopoulos et al 200713 | Greece | Narrative Review |
|
√ | |||
Fu et al 202014 | China | Laboratory (Pre-Clinical) Research |
|
√ | |||
Zhang et al 202015 | Canada | Narrative Review |
|
√ | |||
Rajendran et al 201316 | Japan | Narrative Review |
|
√ | |||
Shoar et al 202017 | USA & Iran | Case Report |
|
√ | |||
Fraietta et al 202018 | Brazil | Narrative Review |
|
√ | |||
Navarra et al 202019 | Italy | Narrative Review |
|
√ | |||
Vishvkarma | & Rajender 202020 | India | Systematic Literature Review |
|
√ | |||
Corona et al 202021 | Italy | Literature Review |
|
√ | |||
Jannini 201722 | Italy | Narrative Review |
|
√ | √ | ||
Abbas et al 202023 | Egypt | Expert Commentary |
|
√ | √ | ||
Mao et al 202024 | China | Case Series |
|
√ | √ | ||
Beghi et al 202025 | Italy | Narrative Review |
|
√ | √ | ||
Thomas & Konstantinidis 202126 | Greece | Narrative Review |
|
√ | √ | ||
Wu et al 202027 | China | Narrative Review |
|
√ | √ | ||
Roychoudhury et al 202128 | India | Narrative Review |
|
√ | √ | ||
Lipsky & Hung 20203 | USA | Narrative Review |
|
√ | √ | ||
Pennanen-Iire et al 202129 | Finland | Narrative Review |
|
√ | √ | √ | |
Riley et al 202030 | USA | Expert Commentary |
|
√ | √ | √ | |
White 20202 | UK | Narrative Review |
|
√ | √ | √ | √ |
Sansone et al 20205 | Italy | Narrative Review |
|
√ | √ | √ | √ |
Sathyanarayana & Andrade 202031 | India | Narrative Review |
|
√ | |||
Paul et al 202032 | Brazil | Expert Commentary |
|
√ | |||
Banerjee & Rao 202033 | India | Narrative Review |
|
√ | |||
Li et al 202034 | China | Patient Survey |
|
√ | |||
McKay et al 202035 | USA | Patient Survey |
|
√ | |||
Maretti et al 202036 | Italy | Narrative Review |
|
√ | |||
Karsiyakali et al 202037 | Turkey | Patient Survey |
|
√ | |||
Fang et al 202038 | China | Patient Survey |
|
√ | |||
De Rose et al 202039 | Italy | Patient Survey |
|
√ | |||
Bulut et al 202140 | Turkey | Patient Survey |
|
√ | |||
Karagöz et al 202041 | Turkey | Patient Survey |
|
√ | |||
Carvalho et al 202042 | Portugal | Expert Commentary |
|
√ | √ | ||
Ruprecht et al 202043 | USA | Patient Survey |
|
√ | √ | √ | |
Purtle 202044 | USA | Expert Commentary |
|
√ | √ | √ | |
Ibrahimi et al 202045 | USA | Expert Commentary |
|
√ | √ | √ | |
Burnett et al 201646 | USA | Literature Review |
|
√ | √ | √ | |
Betron et al 202047 | USA | Expert Commentary |
|
√ | √ | √ | |
Tonyali et al 202048 | Turkey | Narrative Review |
|
√ | |||
Cocci 202049 | Italy | Expert Commentary |
|
√ | |||
Aboumohamed et al 202150 | USA | Urologist Survey |
|
√ | |||
Witherspoon et al 202051 | Canada | Urologist Survey |
|
√ | |||
Vaduganathan et al 202052 | USA | Retrospective Database Analysis |
|
√ | |||
Jeffery et al 202053 | USA | Retrospective Database Analysis |
|
√ | |||
Hartnett et al 202054 | USA | Retrospective Database Analysis |
|
√ | |||
Dooley et al 202055 | USA | Literature Review |
|
√ | |||
Czeisler et al 202056 | USA | Patient Survey |
|
√ | √ | ||
Papautsky et al 202057 | USA | Patient Survey |
|
√ | √ | ||
Klein et al 201058 | USA | Narrative Review |
|
√ | √ | ||
Burnett et al 202059 | USA | Narrative Review |
|
√ | √ | ||
Shindel et al 202060 | USA | Expert Commentary |
|
√ | √ | ||
Mmeje et al 202061 | USA | Expert Commentary |
|
√ | √ | ||
Treadwell 202062 | USA | Expert Commentary |
|
√ | |||
Mulukutla et al 201063 | USA | Prospective Cohort Study |
|
√ | |||
Smith et al 200964 | USA | Patient Survey |
|
√ |
Many of the studies identified in the literature review examined how COVID-19 may affect ED prevalence and severity either directly or indirectly through the extensive impact of the virus on men's genitourinary, cardiovascular, and nervous systems (n = 26; 43.3%). Another large grouping of studies addressed the mental and psychosocial aspects of COVID-19 and ED (n = 28; 46.7%). Twenty-two studies (36.7%) described how COVID-19 had affected patients’ access to ED care and changes in ED management since the pandemic. Disparities in care and the effect of ED and COVID-19 on vulnerable populations was addressed in 18 studies (30.0%). The studies that contributed to each of these four groupings are also noted in Table 1.
DISCUSSION
Four topics emerged regarding the association between COVID-19 and ED: (1) the biological impact of COVID-19 infection on ED; (2) the mental health impact of COVID-19 on ED; (3) the impact of COVID-19 on the management of ED and access to ED treatment; and (4) health disparities and the impact of COVID-19 on ED. Table 1 outlines the topics covered by each of the included studies and Figure 2 illustrates the interactions of the four emergent topics. The following summaries highlight the most significant findings that were revealed for each of the four topics.
Figure 2.
Four topics reflecting the multidimensional impacts of COVID-19 infection on ED.
Topic 1: Biological Impact of COVID-19 Infection on ED
Evidence that COVID-19 may biologically impact ED both in regard to the prevalence of ED (ie, the number of men with ED) and the severity of ED in men with existing ED is beginning to emerge. A retrospective chart review of 12 outpatient urology clinics across Turkey investigated whether there have been variations in the presentations of male patients with sexual and reproductive health problems during the COVID-19 pandemic.10 Andrological problems (ie, ED, premature ejaculation, Peyronie's disease, and priapism, varicocele, infertility, primary/secondary hypogonadism, anejaculation, spermatocele, and undescended testicles) were detected in 721 of 4,955 male patients included in the study. Study findings showed that there was a significant increase in overall andrological diagnosis in these patients during the pandemic period compared with the pre-pandemic period (n = 293 [17%] vs n = 428 [13.2%], P < .001, respectively) (Figure 3 ). The number of patients diagnosed with ED during the pandemic was significantly higher during COVID-19 compared to the pre-COVID-19 pandemic period (n = 150 [8.7%] vs n = 214 [6.6%], P = .008) (Figure 3).10 The authors hypothesized that possible reasons for more frequent presentation to the outpatient urology clinics with ED may include relationship strain due to the “Stay Home” policies, job losses and economic problems, and increased anxiety and depression. Limitations of this study include its retrospective design, lack of randomization, differences in patient baseline characteristics between the comparison groups, and potential confounding from unknown and/or unmeasured variables.
Figure 3.
Andrological diagnoses in male patients pre- and during COVID-19.
An Italian online survey study by Sansone and colleagues (2021) compared the prevalence of ED among men with (n = 75) and without (n = 25) COVID-19 using 3:1 propensity score matching.11 Study findings showed that the prevalence of ED as measured with the Sexual Health Inventory for Men was significantly higher in the COVID-19 group (28.0% vs 9.3%; P = .027). Logistic regression models confirmed a significant effect of COVID-19 on the development of ED, independently of other variables affecting erectile function, such as psychological status, age, and body mass index (BMI). Age, BMI, and psychological health scores failed to reach statistical significance; however, history of COVID-19 was highly significant, resulting in a 5.66 odds ratio (95% confidence interval: 1.50–24.01) of having ED.
The physiology relevant for penile erection may be affected by COVID-19 through vasculogenic, neurogenic, and endocrine mechanisms. A literature review of the possible mechanisms involved in the development of ED in COVID-19 survivors by Sansone and colleagues (2021) found that endothelial dysfunction, subclinical hypogonadism, and impaired pulmonary hemodynamics all contribute to the potential onset of ED.65
Vascular integrity is necessary for erectile function. Accumulating evidence suggests that SARS-COV-2 damages the vascular endothelium,12 the layer of specialized cells lining the inner surfaces of blood vessels and spaces like the surface of the sinusoids of tissues like the corpus cavernosum of the penis.13 The endothelium expresses the protein angiotensin-converting enzyme 2 (ACE2), through which SARS-COV-2 can access host cells.14 , 15 The vascular endothelium regulates the vascular tone, coagulation, metabolism, and permeability of the vessels.13 Endothelial dysfunction results in abnormal regulation of blood pressure, response to inflammation, impairment of the sensitive balance between the vasoconstricting and vasodilating agents and stimuli, and coagulation disorders.13 , 16 Vascular damage associated with COVID-19 is likely to affect the fragile vascular bed of the penis, potentially resulting in impaired erectile function.5 The recognized relationship between vascular health and ED22 suggests an important knowledge gap that could be addressed with translational research to elucidate the penile vascular effects of COVID-19 and their relationship to ED.
ED that manifests during COVID-19 may be a signal for underlying cardiovascular disease and may provide opportunities for earlier assessment of vascular dysfunction. ED, as a surrogate marker of cardiovascular and/or pulmonary health, could become extremely valuable as a quick and inexpensive first-line assessment of the pulmonary and cardiovascular complications for COVID-19 survivors.65 The study by Sansone and colleagues (2021) also measured the likelihood of having a self-reported history of COVID-19 following a diagnosis of ED. Logistic regression models adjusted for age and BMI showed a significant association between ED and COVID-19, with a 5.27 odds ratio [95% CI: 1.49–20.09]. Evidence coming from diagnostic procedures, such as penile color-doppler ultrasound and hypothalamic-pituitary–testicular axis evaluation, may aid in assessing the extent to which COVID-19 has been able to impair erectile, and finally vascular, function.65
COVID-19 may also affect ED prevalence and severity through the indirect impact of the virus on men's cardiovascular system and through the indirect effects of treatments for COVID-19.65 For example, in some cases, COVID-19 may cause acute cardiac injury, leading to a decrease in blood supply to genitalia.23 Also, COVID-19 patients admitted to the ICU who are given thiazide-type diuretics, aldosterone receptor blockers, β-adrenergic receptor blockers, or ACE inhibitors to control blood pressure are believed to be at risk for ED.23
It has been demonstrated that patients with COVID-19 commonly have neurologic manifestations.24 Disorders of the central and peripheral nervous system are present in most COVID-19 patients, while stroke, ataxia, seizures, and depressed level of consciousness are more common in severely affected patients.25 The neurological effects observed in some cases of COVID-19 may also have negative impacts on ED.23 Neurogenic ED consists of a large cohort of ED, accounting for about 10% to 19% of all cases.26 Neurological effects can occur via direct infection injury (blood circulatory pathway and neuronal pathway), hypoxia injury, ACE2, and immune injury27 The tremendous diversity in the etiological factors associated with neurogenic contributors to ED26 combined with the multidimensional effects of COVID-19 demonstrate the importance of further exploring the impact of COVID-19 infections on the nervous system.27
Finally, ED may be affected by COVID-19 through endocrine mechanisms. COVID-19 features a state of hyperinflammation promoted by the same inflammatory cytokines found to be associated with clinical progression of sexual dysfunction (tumor necrosis factor [TNF]-α, interleukin [IL]-6 and IL-1β).5 Although COVID-19 has been shown to cause systemic inflammation predisposing the involvement of multiple organs, the extent of its effect on the urogenital system has not yet been adequately researched.17 It has been theorized that that testicular damage may result following COVID-19 infection.18 , 19 , 28 The ACE2 gene is a receptor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for COVID-19. High levels of ACE2 expression in testes indicate that SARS-CoV-2 might affect the testes, potentially affecting male sexual function.14 , 20 The effects on testicular tissue may harm testosterone production which may, in turn, have an association with ED insofar as its endocrine pathophysiologic risk.65 The more likely effect of testosterone deficiency resulting from COVID-19 infection is decreased sexual libido, and lesser risk on decreasing erection ability.65
Endothelial damage by SARS-COV-2 tied to endothelial expression of ACE2 combined with testosterone's role in modulating endothelial function66 and associated inflammatory effects could be a factor in the differential burden of COVID-19 observed in some men.5 Men at greatest risk for having serious complications secondary to COVID-19 are those traditionally at risk for ED: older adult, diabetic, men with cardiovascular disease, overweight/obesity, and with multiple comorbidities.29 Furthermore, weight gain as a result of the pandemic could have compounding long range adverse effects on the risks for overweight and obesity, diabetes, hypertension, and cardiovascular disease, all of which are associated with ED.31
Topic 2: The Mental Health Impact of COVID-19 on ED
It is important to consider the role of added stress, anxiety, and physical health implications for men with ED amid the COVID-19 pandemic.29 Increased rates of post-traumatic stress disorder (PTSD), depression, and anxiety are expected in the general population, and even more in COVID-19 survivors, following the pandemic.65 Anxiety and depression are commonly seen in men with ED.32 Psychological and mental health issues may lead to ED or worsening ED. ED has been shown to be 1.3–2.3 times more common in individuals with anxiety and depression.67 Although the psychological effects such as depression, anxiety, posttraumatic stress, and sleep disturbances are being studied for COVID-19, literature evaluating the relationship between these psychological and mental consequences and ED is rather scarce.33
Some evidence has shown that sexual behavior was altered during the pandemic, including a reduction in sexual desire and number of sexual partners during the lockdown.34 , 35 The COVID-19 outbreak has dramatically affected men's quality of life by changing inter-personal relationships, community life, and sexual health.36 An Internet-based survey of 1,356 participants in Turkey in June 2020 evaluated sexual function in terms of sexual intercourse frequency and sexual desire during the COVID-19 pandemic using the International Index of Erectile Function (IIEF) and Female Sexual Function Index (FSFI) forms.37 Study findings showed a decline in sexual function during the pandemic period (40.8% had decline in sexual intercourse frequency, 14.0% had decline in frequency of masturbation, and 31.5% had a decline in sexual desire), particularly among individuals living in metropolitan areas.37
An online questionnaire administered to Chinese men (n = 612) during the pandemic (April-May 2020) found that 8.4% and 8.5% subjects reported deteriorated erectile function or ejaculation control ability by self-evaluation, whereas 31.9% and 17.9% subjects showed decreased IIEF-5 scores or increased premature ejaculation diagnostic tool scores.38 Subjects with deteriorated erectile function by self-evaluation and decreased IIEF-5 scores displayed higher General Anxiety Disorder-7 (P < .001 and P = .001) and higher Patient Health Questionnaire-9 score (P < .001 and P = .002) and decreased frequency of sexual life (P < .001 and P < .001) and physical exercise (P = .009 and .007).38 Subjects with decreased frequency of sexual life had reduced income (P < .001), increased anxiety (P < .001) and depression (P < .001).38
A study evaluating sexual activity and depression in a sample of hospital workers and their acquaintances (n = 544) during the COVID-19 lockdown in Italy analyzed responses to the IIEF-15, FSFI, and Beck Depression Inventory.39 Levels of sexual satisfaction were measured with the IIEF-15 overall satisfaction (OS) and intercourse satisfaction (IS) domains. Low satisfaction levels were defined using an arbitrary cut-off score ≤12.5 in the sum of IIEF-IS and IIEF-OS domains. The sexual desire (SD) domain from the IIEF was also recorded and low sexual desire was defined using an arbitrary cut-off score of ≤5. The median (interquartile range) IIEF-Erectile Function score was 10 (3, 11) and the IIEF-Orgasmic Function score was 3 (3, 5). The IIEF-Intercourse Satisfaction score was 5 (0, 7), IIEF-Overall Satisfaction score was 5 (4, 9), and the IIEF-Sexual Desire score was 4 (3, 5).39 To our knowledge, there are no studies clearly defining a cut-off value for abnormal satisfaction domains for the IIEF-15. However, the IIEF validation study by Rosen et al (1997) tested it in a series of 111 men with sexual dysfunction and 109 age-matched, normal volunteer controls.68 The authors found that the mean OS scores were 8.6 for controls and 4.4 for patients, and the mean IS scores were 10.6 for controls and 5.5 for patients.68 On average, controls scored 7.0 in the sexual desire domain and patients scored 6.3.68
The frequency of ED among male healthcare professionals (n = 159) during COVID-19 was also evaluated using the Impact of Event Scale-Revised and the IIEF-5 and compared to a control group of 200 people.40 Both stress disorder and ED were seen at higher rates in healthcare professionals (P < .001).40 The median IIEF-5 scores of male nurses, married subjects, and those working with confirmed COVID-19 patients, were found to be worse (15 [5–24] for physicians vs 10 (5–23) for nurses, P < .001; 16 [5–24] for single vs 12 [5–24] for married, P = .014; 15 [6–24] for suspected patient area vs 11 [5–24] for diagnosed patient area, P = .011).40
A Turkish study evaluating the effect of COVID-19 pandemic on couples' sexuality (n = 245) utilizing the IIEF-15 found that male sexual function scores (IIEF erectile function domain) during the pandemic (May 2020) were statistically significantly lower compared to the pre-pandemic period (pre-pandemic 26.59 ± 4.51 vs during pandemic 24.55 ± 5.79; P = .001).41
Parallels can be drawn between the psychological consequences of COVID-19 and those coming from similar disasters, such as the 9/11 attacks or earthquakes, and similar short- and long-term treatment strategies are, therefore, needed to provide adequate care.65 Tailored psychological interventions may be helpful in supporting patients who develop ED either from the illness itself or as a consequence of the containment measures.65
Topic 3: Impact of COVID-19 on the Management of ED and on Access to ED Treatment
Disruptions in elective and non-emergency medical care access and delivery were observed during COVID-19, particularly during periods of considerable community transmission of SARS-CoV-2.56 , 57 Many elective surgeries for benign urological conditions such as ED were postponed during the COVID-19 outbreak.48, 49, 50 , 69 One example summarizing shifts in men's urological care was published by the Canadian Urological Association.51 It noted the massive shift in only offering surgeries for emergencies and urgent oncology cases with management shifting to mostly virtual care for male sexual health conditions.51 Although not explicitly documented in the published medical literature, it is likely that the evaluation and treatment of ED was also postponed or delayed, potentially prolonging and possibly exacerbating ED problems.
The COVID-19 pandemic and related mitigation measures such as school closures and stay-at-home orders substantially affected patient healthcare- and medication-seeking patterns.52, 53, 54 , 56 , 57 Overall, an estimated 40.9% of US adults avoided medical care during the pandemic because of concerns about COVID-19.56 Age, gender, sexual identity, education, and self-reported worry about general health were significantly associated with experiencing healthcare delays overall.57
The COVID-19 pandemic exposed vulnerabilities within worldwide healthcare and social systems, some of them including services concerning sexual health.42 The need for improved healthcare access was a reality for countless citizens who had never experienced a crisis with such a dimension.42 COVID-19 required healthcare and social systems, clinicians, and citizens to adjust to the digital era in a matter of days.42 E-Health interventions; that is, the increased use of communication and information technologies for health (eg, short message service [SMS], e-mail, video call, cell phone applications, etc.) have been brought to the center of discussion for improved access to healthcare in challenging situations.42 The World Health Organization followed by key professional societies such as the American Psychological Association deemed e-Health a priority target for the improvement of public and universal health.42
The COVID-19 pandemic has accelerated the use of telemedicine and in many ways, sexual medicine healthcare is ideal for telemedicine. Sexual medicine healthcare providers are a highly specialized group of clinicians who are frequently based in metropolitan areas.60 Patients travel great distances to see sexual medicine care providers and telemedicine may increase outreach to patients who cannot otherwise access specialized care.60 The COVID-19 pandemic has offered healthcare professionals an opportunity to re-examine delivery of sexual health services to hard-to-reach and vulnerable populations.61 Providers can increase access to male sexual dysfunction treatment by removing traditional barriers to healthcare that these individuals routinely encounter.61 Rapid advances in telehealth have increased virtual (eg, phone or video) healthcare services and allowed access to confidential and private virtual care.61 Virtual visits can also triage patients for in-person visits required for services.61
Topic 4: Health Disparities and the Impact of COVID-19 on ED
The COVID-19 pandemic has magnified health disparities through loss of work and health insurance, having an impact on employee healthcare coverage and overall access to healthcare. In addition, the COVID-19 outbreak has amplified health disparities by race and gender in the US, perhaps most significantly for African American and Latino men.62 The strain that the outbreak imposed on already resource-constrained health systems undoubtedly disproportionately impacted the health of these individuals.30 African American and Latino men reported significantly lower levels of access to a provider to see if COVID-19 testing would be appropriate (P = .013), lower utilization of medical services (P = .001), and less use of telehealth for mental health services (P = .001).43 The disproportionate social disruption and losses from COVID-19 also contributed to a wide range of health and quality-of-life outcomes amongst these populations.44 , 45
Data regarding disparities in access to ED treatment are scarce. There is some evidence that there are disparities in sexual dysfunction outcomes following prostate cancer treatments in African-American men relative to ethnically different counterparts.46 Disparities in urologic healthcare delivery and access; however, have been more thoroughly researched and documented in the published medical literature. These studies have demonstrated that there are apparent differences in urologic healthcare delivery and access among racial and ethnic groups in the US.58 This has been shown in urologic cancer screening, treatment choices, and survival, as well as in the arena of chronic kidney disease, transplant allocation, and transplant outcomes.58
Healthcare barriers that inhibit support for men seeking care for ED were already in existence before COVID-19,59 and the disparities in access to all healthcare were exacerbated by the pandemic.56 This further reinforces the need to ensure that these ED treatment barriers are not additionally amplified. A greater focus must be paid to health equity, including providing increased resources and supplies for affected groups, adapting to inequities in the existing environment, and ensuring adequate access to healthcare services to ameliorate the burden of COVID-19 on African American and Latino male respondents.43
Aside from disparities in access to healthcare, other factors may also play a role in the differential impact of COVID-19 on particular subgroups of vulnerable populations. There is some evidence that Latino men may be affected more often by ED than Caucasian men in the US.58 Evidence of racial differences in endothelial function has been known for over a decade; black race is independently associated with arterial endothelial function and this plays a role in overall cardiovascular risk.63 A previous study found that the prevalence of ED among different racial and ethnic groups in the US is the result of complex phenomena and may be dependent upon the interplay of socioeconomic, demographic, medical, cultural, and lifestyle characteristics.64
Pathways Forward
The COVID-19 pandemic has brought to light a remarkable awareness on many health and social issues, including ED and men's health.42 The four topics that emerged from the scoping review illustrate the far-reaching effects of COVID-19 on ED. Evidence that the COVID-19 pandemic may precipitate or worsen ED through biological and mental health effects is emerging and compelling. Preliminary evidence showed a significant association between ED and COVID-19, with a 5.27 odds ratio [95% CI: 1.49–20.09]. Multiple pathways and factors associated with ED and the significance of COVID-19 were identified in the published medical literature (Figure 4 ).
Figure 4.
Pathways and factors associated with ED and the significance of COVID-19.
There is reason to suspect that impaired vascular function and ED might persist in COVID-19 survivors and even become a public health issue.65 In patients recovered from COVID-19, ED evaluation and consultation may be important.21 Getting effective public health messages out to the population is vital and this current pandemic has demonstrated the need for more focused views on men's sexual health.2 , 3
Studies with larger cohorts of subjects who were infected with COVID-19 are needed to evaluate the degree of impact on men's health.21 As data accumulate in administrative health databases, retrospective analyses may be conducted to better understand the patterns of interactions that men with ED had with the healthcare system through COVID-19 and to capture the extent of the impact of COVID-19 on pre-existing and emergent ED. Patient surveys such as the National Health and Nutrition Examination Survey and the National Ambulatory Medical Care Survey may be helpful in collecting patients’ experiences with ED during and after COVID-19.
There are several limitations of this scoping review. Given the breadth of topics reviewed from the 693 peer-reviewed articles, we did not conduct a formal systematic review or meta-analysis. Moreover, given the paucity of primary data showing the relationship between COVID-19 infection and ED, many unanswered questions remain. In addition, publication bias may have affected the reported relationships and we were unable to assess the magnitude of publication bias given the limited studies. Finally, the generalizability of the findings may be limited given the significant variability in the underlying causes of and the varying healthcare systems, practices, and health infrastructure across the globe.
CONCLUSIONS
In conclusion, this scoping review of the literature showed emerging evidence that COVID-19 has a uniquely harmful impact on men's health and erectile function through biological, mental health, and healthcare access mechanisms. ED could be a concerning consequence for a large segment of the male population given the high transmissibility of COVID-19; therefore, long-term and well-designed studies are needed to clarify the extent of the impact of COVID-19 on ED. Men presenting with ED after COVID-19 infection may have underlying endothelial dysfunction and vasculature issues and hence pulmonary and cardiovascular complications from COVID-19. A strategic focus on gender in the COVID-19 response will be critical for mitigating the impacts of the pandemic.3 , 47 The pandemic exposed vulnerabilities within worldwide healthcare and social systems, some of them including services concerning sexual health.42 Telemedicine may be helpful in diagnosing and treating sexual medicine patients55 and in ameliorating the burden of COVID-19 on vulnerable and marginalized populations.
STATEMENT OF AUTHORSHIP
Category 1
(a) Conception and Design
Tung-Chin Hsieh; Natalie C. Edwards; Samir K. Bhattacharyya; Krista D. Nitschelm; Arthur L. Burnett
(b) Acquisition of Data
Tung-Chin Hsieh; Natalie C. Edwards; Samir K. Bhattacharyya; Krista D. Nitschelm; Arthur L. Burnett
(c) Analysis and Interpretation of Data
Tung-Chin Hsieh; Natalie C. Edwards; Samir K. Bhattacharyya; Krista D. Nitschelm; Arthur L. Burnett
Category 2
(a) Drafting the Manuscript
Tung-Chin Hsieh; Natalie C. Edwards; Krista D. Nitschelm
(b) Revising It for Intellectual Content
Tung-Chin Hsieh; Natalie C. Edwards; Samir K. Bhattacharyya; Krista D. Nitschelm; Arthur L. Burnett
Category 3
(a) Final Approval of the Completed Manuscript
Tung-Chin Hsieh; Natalie C. Edwards; Samir K. Bhattacharyya; Krista D. Nitschelm; Arthur L. Burnett
Footnotes
Conflict of Interest: This review was supported by Boston Scientific, who reviewed and provided feedback on the manuscript. The authors had full editorial control of the manuscript and provided their final approval of all content.
Funding: None.
REFERENCES
- 1.Lisco G, Giagulli VA, De Pergola G, et al. Covid-19 in man: a very dangerous affair. Endocr Metab Immune Disord Drug Targets. DOI: 10.2174/1871530321666210101123801. E-pub ahead of print. [DOI] [PubMed]
- 2.White A. Men and COVID-19: the aftermath. Postgraduate Med. 2020;132:18–27. doi: 10.1080/00325481.2020.1823760. [DOI] [PubMed] [Google Scholar]
- 3.Lipsky MS, Hung M. Men and COVID-19: a pathophysiologic review. Am J Mens Health. 2020;14 doi: 10.1177/1557988320954021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Pijls BG, Jolani S, Atherley A, et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies. BMJ Open. 2021;11 doi: 10.1136/bmjopen-2020-044640. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Sansone A, Mollaioli D, Ciocca G, et al. Addressing male sexual and reproductive health in the wake of COVID-19 outbreak. J Endocrinol Invest. 2021;44:223–231. doi: 10.1007/s40618-020-01350-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Peters MD, Godfrey CM, Khalil H, et al. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc. 2015;13:141–146. doi: 10.1097/XEB.0000000000000050. [DOI] [PubMed] [Google Scholar]
- 7.Munn Z, Peters MDJ, Stern C, et al. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18:143. doi: 10.1186/s12874-018-0611-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Pham MT, Rajić A, Greig JD, et al. A scoping review of scoping reviews: advancing the approach and enhancing the consistency. Res Synth Methods. 2014;5:371–385. doi: 10.1002/jrsm.1123. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (prisma-scr): checklist and explanation. Ann Intern Med. 2018;169:467–473. doi: 10.7326/M18-0850. [DOI] [PubMed] [Google Scholar]
- 10.Duran MB, Yildirim O, Kizilkan Y, et al. Variations in the number of patients presenting with andrological problems during the coronavirus disease 2019 pandemic and the possible reasons for these variations: a multicenter study. Sex Med. 2021;9 doi: 10.1016/j.esxm.2020.100292. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Sansone A, Mollaioli D, Ciocca G, et al. Mask up to keep it up: Preliminary evidence of the association between erectile dysfunction and COVID-19. Andrology. 2021 doi: 10.1111/andr.13003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Jin Y, Ji W, Yang H, et al. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches. Signal Transduct Target Ther. 2020;5:293. doi: 10.1038/s41392-020-00454-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Konstantinopoulos A, Giannitsas K, Raptis S, Perimenis P. Endothelial dysfunction, erectile dysfunction and phosphodiesterase 5 inhibitors. An update of the current data and future perspectives. Drug Target Insights. 2007;2:111–117. [PMC free article] [PubMed] [Google Scholar]
- 14.Fu J, Zhou B, Zhang L, et al. Expressions and significances of the angiotensin-converting enzyme 2 gene, the receptor of SARS-CoV-2 for COVID-19. Mol Biol Rep. 2020;47:4383–4392. doi: 10.1007/s11033-020-05478-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Zhang H, Penninger JM, Li Y, et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46:586–590. doi: 10.1007/s00134-020-05985-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Rajendran P, Rengarajan T, Thangavel J, et al. The vascular endothelium and human diseases. Int J Biol Sci. 2013;9:1057–1069. doi: 10.7150/ijbs.7502. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Shoar S, Khavandi S, Tabibzadeh E, et al. A Late COVID-19 complication: male sexual dysfunction. Prehosp Disaster Med. 2020;35:688–689. doi: 10.1017/S1049023X20001223. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Fraietta R, Pasqualotto FF, Roque M, et al. SARS-COV-2 and male reproductive health. JBRA Assist Reprod. 2020;24:347–350. doi: 10.5935/1518-0557.20200047. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Navarra A, Albani E, Castellano S, et al. Coronavirus disease-19 infection: implications on male fertility and reproduction. Front Physiol. 2020;11 doi: 10.3389/fphys.2020.574761. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Vishvkarma R, Rajender S. Could SARS-CoV-2 affect male fertility? Andrologia. 2020;52:e13712. doi: 10.1111/and.13712. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Corona G, Baldi E, Isidori AM, et al. SARS-CoV-2 infection, male fertility and sperm cryopreservation: a position statement of the Italian Society of Andrology and Sexual Medicine (SIAMS) (Società Italiana di Andrologia e Medicina della Sessualità) J Endocrinol Invest. 2020;43:1153–1157. doi: 10.1007/s40618-020-01290-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Jannini EA. SM = SM: the interface of systems medicine and sexual medicine for facing non-communicable diseases in a gender-dependent manner. Sex Med Rev. 2017;5:349–364. doi: 10.1016/j.sxmr.2017.04.002. [DOI] [PubMed] [Google Scholar]
- 23.Abbas AM, Fathy SK, Khamees AA, et al. A focused review on the genital and sexual affection of COVID-19 patients. J Gynecol Obstet Hum Reprod. 2020;49 doi: 10.1016/j.jogoh.2020.101848. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77:683–690. doi: 10.1001/jamaneurol.2020.1127. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Beghi E, Feigin V, Caso V, et al. COVID-19 infection and neurological complications: present findings and future predictions. Neuroepidemiology. 2020;54:364–369. doi: 10.1159/000508991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Thomas C, Konstantinidis C. Neurogenic erectile dysfunction. where do we stand? Medicines. 2021;8:3. doi: 10.3390/medicines8010003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Wu Y, Xu X, Chen Z, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020;87:18–22. doi: 10.1016/j.bbi.2020.03.031. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Roychoudhury S, Das A, Jha NK, et al. Viral pathogenesis of SARS-CoV-2 infection and male reproductive health. Open Biol. 2021;11 doi: 10.1098/rsob.200347. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Pennanen-Iire C, Prereira-Lourenço M, Padoa A, et al. Sexual health implications of COVID-19 pandemic. Sex Med Rev. 2021;9:3–14. doi: 10.1016/j.sxmr.2020.10.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Riley T, Sully E, Ahmed Z, et al. Estimates of the potential impact of the COVID-19 pandemic on sexual and reproductive health in low- and middle-income countries. Int Perspect Sex Reprod Health. 2020;46:73–76. doi: 10.1363/46e9020. [DOI] [PubMed] [Google Scholar]
- 31.Sathyanarayana Rao TS, Andrade C. Sexual behavior in the days of COVID-19. J Psychosexual Health. 2020;2:111–112. [Google Scholar]
- 32.Paul GM, Nascimento BC, Afif-Abdo J, et al. The psychiatric impact of COVID-19 pandemic on sexual health. Braz J Psychiatry. 2020 doi: 10.1590/1516-4446-2020-1197. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Banerjee D, Rao TSS. Sexuality, sexual well being, and intimacy during COVID-19 pandemic: an advocacy perspective. Indian J Psychiatry. 2020;62:418–426. doi: 10.4103/psychiatry.IndianJPsychiatry_484_20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Li W, Li G, Xin C, et al. Challenges in the practice of sexual medicine in the time of COVID-19 in China. J Sexual Med. 2020;17:1225–1228. doi: 10.1016/j.jsxm.2020.04.380. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.McKay T, Henne J, Gonzales G, et al. The COVID-19 pandemic and sexual behavior among gay and bisexual men in the United States. SSRN Electronic J DOI: 10.1007/s13178-021-00625-3. E-pub ahead of print. [DOI]
- 36.Maretti C, Privitera S, Arcaniolo D, et al. COVID-19 pandemic and its implications on sexual life: recommendations from the Italian society of andrology. Arch Ital Urol Androl. 2020;92 doi: 10.4081/aiua.2020.2.73. [DOI] [PubMed] [Google Scholar]
- 37.Karsiyakali N, Sahin Y, Ates HA, et al. Evaluation of the sexual functioning of individuals living in turkey during the covid-19 pandemic: an internet-based nationwide survey study. Sex Med. 2020;9 doi: 10.1016/j.esxm.2020.10.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Fang D, Peng J, Liao S, et al. An online questionnaire survey on the sexual life and sexual function of Chinese adult men during the coronavirus disease 2019 epidemic. Sex Med. 2020;9 doi: 10.1016/j.esxm.2020.100293. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.De Rose AF, Chierigo F, Ambrosini F, et al. Sexuality during COVID lockdown: a cross-sectional Italian study among hospital workers and their relatives. Int J Impot Res. 2021;33:131–136. doi: 10.1038/s41443-020-00393-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Bulut EC, Ertaş K, Bulut D, et al. The effect of COVID-19 epidemic on the sexual function of healthcare professionals. Andrologia. 2021;53:e13971. doi: 10.1111/and.13971. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Karagöz MA, Gül A, Borg C, et al. Influence of COVID-19 pandemic on sexuality: a cross-sectional study among couples in Turkey. Int J Impot Res DOI: 10.1038/s41443-020-00378-4. E-pub ahead of print. [DOI] [PMC free article] [PubMed]
- 42.Carvalho J, Pascoal PM. Challenges in the practice of sexual medicine in the time of COVID-19 in Portugal. J Sex Med. 2020;17:1212–1215. doi: 10.1016/j.jsxm.2020.05.024. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Ruprecht MM, Wang X, Johnson AK, et al. Evidence of Social and Structural COVID-19 Disparities by Sexual Orientation, Gender Identity, and Race/Ethnicity in an Urban Environment. J Urban Health. 2021;98:27–40. doi: 10.1007/s11524-020-00497-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Purtle J. COVID-19 and mental health equity in the United States. Soc Psychiatry Psychiatr Epidemiol. 2020;55:969–971. doi: 10.1007/s00127-020-01896-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Ibrahimi S, Yusuf KK, Dongarwar D, et al. COVID-19 devastation of african american families: impact on mental health and the consequence of systemic racism. Int J MCH AIDS. 2020;9:390–393. doi: 10.21106/ijma.408. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Burnett AL. racial disparities in sexual dysfunction outcomes after prostate cancer treatment: myth or reality? J Racial Ethn Health Disparities. 2016;3:154–159. doi: 10.1007/s40615-015-0126-7. [DOI] [PubMed] [Google Scholar]
- 47.Betron M, Gottert A, Pulerwitz J, et al. Men and COVID-19: adding a gender lens. Glob Public Health. 2020;15:1090–1092. doi: 10.1080/17441692.2020.1769702. [DOI] [PubMed] [Google Scholar]
- 48.Tonyali S, Haberal HB, Ergul R, et al. Management of patients who seek urologic care in Covid-19 pandemic era. Urol J. 2020;17:548–554. doi: 10.22037/uj.v16i7.6285. [DOI] [PubMed] [Google Scholar]
- 49.Cocci A, Presicce F, Russo GI, et al. How sexual medicine is facing the outbreak of COVID-19: experience of Italian urological community and future perspectives. Int J Impot Res. 2020;32:480–482. doi: 10.1038/s41443-020-0270-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Aboumohamed A, Gottlieb J, DeMasi M, et al. Methodology for triage of urologic surgical cases in the setting of a pandemic. BMC Surg. 2021;21:116. doi: 10.1186/s12893-021-01067-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Witherspoon L, Fitzpatrick R, Patel P, et al. Clinical pearls to managing men's health conditions during the COVID-19 pandemic. Can Urol Assoc J. 2020;14:E161–EE66. doi: 10.5489/cuaj.6631. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Vaduganathan M, van Meijgaard J, et al. Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States. JAMA. 2020;323:2524–2526. doi: 10.1001/jama.2020.9184. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Jeffery MM, D'Onofrio G, Paek H, et al. Trends in emergency department visits and hospital admissions in health care systems in 5 states in the first months of the COVID-19 Pandemic in the US. JAMA Int Med. 2020;180:1328–1333. doi: 10.1001/jamainternmed.2020.3288. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Hartnett KP, Kite-Powell A, DeVies J, et al. Impact of the COVID-19 pandemic on emergency department visits - United States, January 1, 2019-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:699–704. doi: 10.15585/mmwr.mm6923e1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Dooley AB, Houssaye N, Baum N. Use of telemedicine for sexual medicine patients. Sex Med Rev. 2020;8:507–517. doi: 10.1016/j.sxmr.2020.06.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Czeisler M, Marynak K, Clarke K, et al. Delay or avoidance of medical care because of COVID-19-related concerns - United States, June 2020. MMWR. 2020;69:1250–1257. doi: 10.15585/mmwr.mm6936a4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Papautsky EL, Rice D, Ghoneima H, et al. Characterizing healthcare delays and interruptions in the us during the covid-19 pandemic: data from an internet-based cross-sectional survey. J Med Internet Res. 2021;23 doi: 10.2196/25446. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Klein JB, Nguyen CT, Saffore L, et al. Racial disparities in urologic health care. J Natl Med Assoc. 2010;102:108–117. doi: 10.1016/s0027-9684(15)30498-3. [DOI] [PubMed] [Google Scholar]
- 59.Burnett AL, Edwards NC, Barrett TM, et al. Addressing health-care system inequities in the management of erectile dysfunction: a call to action. Am J Mens Health. 2020;14 doi: 10.1177/1557988320965078. 1557988320965078. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Shindel AW, Rowen TS. Challenges in the practice of sexual medicine in the time of COVID-19 in the United States. J Sexual Med. 2020;17:1216–1219. doi: 10.1016/j.jsxm.2020.05.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Mmeje OO, Coleman JS, Chang T. Unintended consequences of the COVID-19 pandemic on the sexual and reproductive health of youth. J Adolesc Health. 2020;67:326–327. doi: 10.1016/j.jadohealth.2020.06.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Treadwell HM. The pandemic, racism, and health disparities among African American men. Am J Mens Health. 2020;14 doi: 10.1177/1557988320949379. 1557988320949379-79. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Mulukutla SR, Venkitachalam L, Bambs C, et al. Black race is associated with digital artery endothelial dysfunction: results from the Heart SCORE study. Eur Heart J. 2010;31:2808–2815. doi: 10.1093/eurheartj/ehq295. [DOI] [PubMed] [Google Scholar]
- 64.Smith JF, Caan BJ, Sternfeld B, et al. Racial disparities in erectile dysfunction among participants in the California Men's Health Study. J Sex Med. 2009;6:3433–3439. doi: 10.1111/j.1743-6109.2009.01519.x. [DOI] [PubMed] [Google Scholar]
- 65.Sansone A, Mollaioli D, Ciocca G, et al. Addressing male sexual and reproductive health in the wake of COVID-19 outbreak. J Endocrinol Invest. 2021;44:223–231. doi: 10.1007/s40618-020-01350-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Isidori AM, Buvat J, Corona G, et al. A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-a systematic review. Eur Urol. 2014;65:99–112. doi: 10.1016/j.eururo.2013.08.048. [DOI] [PubMed] [Google Scholar]
- 67.Dunn KM, Croft PR, Hackett GI. Association of sexual problems with social, psychological, and physical problems in men and women: a cross sectional population survey. J Epidemiol Commun Health. 1999;53:144–148. doi: 10.1136/jech.53.3.144. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822–830. doi: 10.1016/s0090-4295(97)00238-0. [DOI] [PubMed] [Google Scholar]
- 69.American College of Surgeons (ACS). COVID-19: guidance for triage of non-emergent surgical procedures. J Am Coll Surg. 2020;231:490–496. [Google Scholar]